Virios Therapeutics Inc

Change company Symbol lookup

Select an option...

VIRI Virios Therapeutics Inc

GTEC Greenland Technologies Holding Corp

STR Sitio Royalties Corp

CWD CaliberCos Inc

LNTH Lantheus Holdings Inc

DFIN Donnelley Financial Solutions Inc

SY So-Young International Inc

GOTU Gaotu Techedu Inc

SGDVV Safe & Green Development Corp

GLBZ Glen Burnie Bancorp

Go

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).